---
title: "Weekly Recap | SPDR S&P Biotech -0.39%, busy week of biotech headlines"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300842242.md"
description: "XBI.US closed the week at $154.43, down 0.39%, while the S&P 500 fell 0.27% over the same period, leaving the ETF about 0.12 percentage points behind. The week opened at $156.61 on Monday, moved up to $157.68 by Wednesday, then pulled back for two straight sessions. Thursday recorded the highest daily volume of the week at 11.6m shares as the price slipped from the week high of $159.98 toward the low of $153.575. Average daily volume of 8."
datetime: "2026-10-03T05:05:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300842242.md)
  - [en](https://longbridge.com/en/news/300842242.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300842242.md)
generator: "portal-rs"
---

# Weekly Recap | SPDR S&P Biotech -0.39%, busy week of biotech headlines

## The Week

XBI.US closed the week at $154.43, down 0.39%, while the S&P 500 fell 0.27% over the same period, leaving the ETF about 0.12 percentage points behind. The week opened at $156.61 on Monday, moved up to $157.68 by Wednesday, then pulled back for two straight sessions. Thursday recorded the highest daily volume of the week at 11.6m shares as the price slipped from the week high of $159.98 toward the low of $153.575. Average daily volume of 8.55m shares was roughly in line with the 60-day median, an overall pattern of a failed rally.

## Sector News

The biotech tape was busy this week. Iovance lifted its FY 2026 total revenue guidance to $410m-$420m, sending the stock to its highest level since 2024, with Barclays and HC Wainwright then rating it buy. AbbVie published positive data across atopic dermatitis, an obesity candidate and long-term vitiligo results, and secured EU approval for paediatric arthritis use. Amgen and Biogen diverged, with Amgen down 3.38% on Wednesday while Biogen swung between outperforming and lagging peers. Moderna drew attention after Citi downgraded the stock following a sharp rally, and the company also lost a government license defence in a Northwestern patent case. United Therapeutics prevailed in patent litigation against Liquidia, leaving Liquidia under pressure for the week.

## The Week Ahead

Macro data kicks off the week: on 5 October, the S&P Global services PMI final and ISM non-manufacturing PMI are due, with prior readings of 58.7 and 55.4; on 6 October, trade balance figures arrive. Midweek brings EIA crude inventory data. On the biotech side, the market will watch how Iovance’s raised guidance holds up and whether the Moderna downgrade and patent dispute produce further follow-through.

## In Short

XBI.US slipped only modestly this week, but beneath the surface the sector was split. Positive clinical readouts and a raised revenue guide lifted select names, while patent rulings and rating cuts weighed on Moderna and Liquidia. The ETF’s latest price of $154.43 sits below the 20-day moving average of $157.27, and the most recent session showed large-lot money turning net seller while small and medium orders were net buyers, a split between institutional and retail direction. After retreating from the recent range high of $169.89, the key question is whether biotech can rebuild upward momentum as macro data and single-stock news land next week.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [ROI-Oil's new problem isn't supply. It's logistics: Bousso](https://longbridge.com/en/news/300903866.md)
- [TECHNICALS-US oil may retest support at $88.78](https://longbridge.com/en/news/300892493.md)
- [SoundHound AI Stock: Is it a Bargain Buy at $6?](https://longbridge.com/en/news/300942708.md)
- [Michael Burry Raises Red Flag on Oracle’s $664B Backlog and AI Spending: ‘The Customer Is Now the Lender’](https://longbridge.com/en/news/300913488.md)
- [Western Digital vs. Sandisk: The Better Way to Play the Hard-Drive Side of the AI Storage Boom](https://longbridge.com/en/news/300870855.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**